Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses

PHASE1CompletedINTERVENTIONAL

Enrollment

107

Participants

Timeline

Start Date

February 28, 2009

Study Completion Date

May 31, 2009

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG

AZD4017

ascending multiple doses(start dose 75mg od), oral suspension

DRUG

Placebo

Trial Locations (1)

Research Site, Gothenburg